沐舒坦在呼吸道感染独特作用.pptVIP

内容提要 一、肺部感染概况 二、沐舒坦独特的肺部作用机制 内容提要 一、肺部感染概况 二、沐舒坦独特的肺部作用机制 纤毛功能 1、纤毛摆动频率：大约每分钟1000次。 2、黏液移动速度：每分钟2厘米。 3、一个纤毛上皮细胞有 250 条纤毛， 4、纤毛运动有一定的方向性，并呈波浪式滚动。 气道自洁系统立体观 这是沐舒坦?针产品的信息。独有5年有效期，是沐舒坦原研药品的独有品质。 * 备选 Abstract Ambroxol [trans-4-(2-amino-3,5-dibromobenzylamino)-cyclohexanole hydrochloride], a mucolytic agent, was postulated to provide surfactant stimulatory properties and was previously used to prevent surfactant deficiency. Currently, the underlying mechanisms are not exactly clear.Because surfactant homeostasis is regulated by surfactant-specific proteins (SP), we analyzed protein amount and mRNA expression in whole lung tissue, isolated type II pneumocytes and bronchoalveolar lavage of Sprague–Dawley rats treated with ambroxol i.p. (75 mg/kg body weight, twice a day [every 12 h]). The methods used included competitive polymerase chain reaction (RT-PCR), Northern blotting, Western immunoblotting, and immunohistochemistry. In isolated type II pneumocytes of ambroxol-treated animals, SP-C protein and mRNA content were increased, whereas SP-A, -B and –D protein, mRNA, and immunoreactivity remained unaffected. However, ambroxol treatment resulted in a significant increase of SP-B and in a decrease of SP-D in whole lung tissue with enhanced immunostaining for SP-B in Clara Cells. SP-A and SP-D were significantly decreased in BAL fluid of ambroxol-treated animals. The data suggest that surfactant protein expression is modulated in a cell-specific manner by ambroxol, as type II pneumocytes exhibited an increase in SP-C, whereas Clara cells exhibited an increase in the immunoreactivity for SP-B accounting for the increased SP-B content of whole lung tissue. The results indicate that ambroxol may exert its positive effects, observed in the treatment of diseases related to surfactant deficiency, via modulation of surfactant protein expression. * * * 接下来，我将用一些临床研究实例来说明沐舒坦对抗生素协同作用。 首先介绍一项意大利的研究——沐舒坦对慢性呼吸道疾病患者抗生素生物利用度的影响。 * 研究者将60例 COPD 患者，随机分为3组，每组20例。3组分别使用3种不同的抗生素，分别为阿莫西林、红